Orforglipron vs Noopept
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronCognitive Enhancement
Noopept- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Noopept is a potent dipeptide-derived nootropic from Russia, structurally related to piracetam but estimated to be 1,000 times more potent by mass. It enhances memory consolidation, learning, and recall while providing neuroprotection via BDNF and NGF upregulation.
- Half-Life
- ~12 hours (once-daily oral dosing)
- ~5–10 minutes but metabolite (CPG) effects last hours
- Admin Route
- Oral
- Oral, Sublingual, Intranasal
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 10–30 mg
- Frequency
- Once daily
- 1–2x daily
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Enhances memory formation and recall
- Improves learning speed and cognitive processing
- Neuroprotective via BDNF/NGF upregulation
- Anxiolytic at low-to-moderate doses
- Improves verbal fluency and information processing
- Antioxidant (reduces oxidative damage in neurons)
- May improve cognitive symptoms of mild cognitive impairment
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Headaches (choline depletion — pair with choline source)
- Irritability or anxiety at high doses
- Overstimulation
- Rare: brain fog with chronic use
- +1 more
- Stacks With
- —
- —